PTC Therapeutics Inc Total Assets
PTC Therapeutics Inc total assets. Based on the latest financial reports, PTC Therapeutics Inc (PTCT) holds total assets worth $2.87 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see PTC Therapeutics Inc (PTCT) cash flow conversion for how efficiently the company converts equity into cash flow.
Total Assets of PTC Therapeutics Inc (2004–2025)
Total assets of PTC Therapeutics Inc from 2004 to 2025. This chart illustrates how PTC Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See latest PTC Therapeutics Inc stock price today for real-time trading data and today's change.
PTC Therapeutics Inc - Asset Composition Analysis
PTC Therapeutics Inc Total Assets Breakdown (December 2025)
PTC Therapeutics Inc total assets breakdown as of December 2025. PTC Therapeutics Inc's total assets of $2.87 Billion consist of 78.1% current assets and 21.9% non-current assets. Explore working capital position of PTC Therapeutics Inc to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.8% |
| Accounts Receivable | $181.62 Million | 6.2% |
| Inventory | $79.65 Million | 2.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $388.75 Million | 13.4% |
| Goodwill | $82.34 Million | 2.8% |
Asset Composition Trend (2004–2025)
This chart illustrates how PTC Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PTC Therapeutics Inc's current assets represent 78.1% of total assets in 2025, an increase from 0.0% in 2004.
- Cash Position: Cash and equivalents constituted 33.8% of total assets in 2025, up from 17.4% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 13.4% of total assets.
PTC Therapeutics Inc Competitors by Total Assets
Key competitors of PTC Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.98 Billion |
PTC Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.44 | 3.89 | 3.66 |
| Quick Ratio | 2.36 | 3.85 | 3.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.33 Billion | $1.72 Billion | $775.27 Million |
PTC Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between PTC Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1743.27 |
| Latest Market Cap to Assets Ratio | 1.84 |
| Asset Growth Rate (YoY) | 70.7% |
| Total Assets | $2.91 Billion |
| Market Capitalization | $5.35 Billion USD |
Valuation Analysis
Above Book Valuation: The market values PTC Therapeutics Inc's assets above their book value (1.84x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: PTC Therapeutics Inc's assets grew by 70.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PTC Therapeutics Inc (2004–2025)
The table below shows the annual total assets of PTC Therapeutics Inc from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.91 Billion | +70.75% |
| 2024-12-31 | $1.71 Billion | -10.06% |
| 2023-12-31 | $1.90 Billion | +11.14% |
| 2022-12-31 | $1.71 Billion | -11.99% |
| 2021-12-31 | $1.94 Billion | -12.24% |
| 2020-12-31 | $2.21 Billion | +36.00% |
| 2019-12-31 | $1.62 Billion | +45.08% |
| 2018-12-31 | $1.12 Billion | +185.77% |
| 2017-12-31 | $391.65 Million | +45.41% |
| 2016-12-31 | $269.35 Million | -26.82% |
| 2015-12-31 | $368.04 Million | +10.45% |
| 2014-12-31 | $333.22 Million | +119.36% |
| 2013-12-31 | $151.90 Million | +1062.02% |
| 2012-12-31 | $13.07 Million | -70.39% |
| 2011-12-31 | $44.15 Million | +0.40% |
| 2005-12-31 | $43.97 Million | +12.85% |
| 2004-12-31 | $38.97 Million | -- |
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervo… Read more